Verastem Inc
VSTM
Company Profile
Business description
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Contact
117 Kendrick Street
Suite 500
NeedhamMA02494
USAT: +1 781 292-4200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
78
Stocks News & Analysis
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
We raise our fair value estimate for Oracle stock.
stocks
US dividend shares are getting a boost from the HALO trade. Can it last?
Both high-dividend stocks and dividend-growth stocks are outperforming amid AI disruption.
stocks
Unconventional wisdom: A modern day bank run
Is the economy and investor portfolios at risk from a potential ‘bank run’ in private credit?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,839.10 | 26.30 | 0.30% |
| CAC 40 | 7,911.53 | 145.83 | -1.81% |
| DAX 40 | 23,447.29 | 142.36 | -0.60% |
| Dow JONES (US) | 46,558.47 | 119.38 | -0.26% |
| FTSE 100 | 10,261.15 | 44.00 | -0.43% |
| HKSE | 25,465.60 | 251.16 | -0.98% |
| NASDAQ | 22,105.36 | 206.62 | -0.93% |
| Nikkei 225 | 53,819.61 | 633.35 | -1.16% |
| NZX 50 Index | 13,197.51 | 10.17 | 0.08% |
| S&P 500 | 6,632.19 | 40.43 | -0.61% |
| S&P/ASX 200 | 8,617.10 | 29.20 | 0.34% |
| SSE Composite Index | 4,095.45 | 33.65 | -0.82% |